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Abstract: 
The grapefruit juice (GFJ)–fexofenadine interaction involves inhibition of intestinal organic 
anion transporting polypeptide (OATP)-mediated uptake. Only naringin has been shown 
clinically to inhibit intestinal OATP; other constituents have not been evaluated. The effects of a 
modified GFJ devoid of furanocoumarins (∼99%) and polymethoxyflavones (∼90%) on 
fexofenadine disposition were compared to effects of the original juice. Extracts of both juices 
inhibited estrone 3-sulfate and fexofenadine uptake by similar extents in OATP-transfected cells 
(∼50% and ∼25%, respectively). Healthy volunteers (n = 18) were administered fexofenadine 
(120 mg) with water, GFJ, or modified GFJ (240 mL) by randomized, three-way crossover 
design. Compared to water, both juices decreased fexofenadine geometric mean AUC and Cmax 
by ∼25% (P ≤ .008 and P ≤ .011, respectively), with no effect on terminal half-life (P = .11). 
Similar effects by both juices on fexofenadine pharmacokinetics indicate furanocoumarins and 
polymethoxyflavones are not major mediators of the GFJ–fexofenadine interaction. 
Keywords: clinical pharmacology | clinical research | gastrointestinal | pharmacokinetics | drug 
metabolism 
Article: 
The drug interaction liability of grapefruit juice (GFJ) and individual constituents has been 
studied extensively for more than 20 years.[1] GFJ–drug interactions can manifest clinically as 
increased systemic drug exposure and subsequent adverse reactions due to mechanism-based 
inhibition of cytochrome P450 3A (CYP3A)-mediated metabolism in the intestine by GFJ.[2, 3] A 
class of constituents, furanocoumarins, was established as major mediators of this effect.[3-5] A 
different type of GFJ interaction was reported in 2002, when the non-sedating, minimally 
metabolized antihistamine fexofenadine was used as a probe substrate for examining the effect of 
GFJ on the efflux transporter, P-glycoprotein (P-gp), in the intestine.[6] Healthy volunteers 
administered fexofenadine with GFJ exhibited an unexpected mean 63% decrease in 
fexofenadine exposure. This seemingly paradoxical effect was observed consistently in four 
independent clinical studies reported over the subsequent five years.[7-10] The underlying 
mechanism was postulated to involve inhibition of fexofenadine active uptake in the intestine by 
organic anion transporting polypeptides (OATPs). Three clinical studies demonstrated that the 
size and flare of histamine-induced skin wheals were increased after administration of 
fexofenadine with GFJ or orange juice but not water.[11] Population pharmacokinetic analysis of 
the combined data from these studies and a bioequivalence study showed that the oral 
availability of fexofenadine was reduced by 36%. Due to the potential for reduced therapeutic 
efficacy, the labeling of all fexofenadine products recommends taking the drug with water. 
Constituents in GFJ have been identified as OATP inhibitors in vitro,[10, 12] but the flavanone, 
naringin, is the only single constituent tested clinically.[10] Relative to water, GFJ and an aqueous 
solution of naringin at the same concentration as that in GFJ (∼1,200 µmol/L) decreased 
fexofenadine mean exposure by 42% and 22%, respectively. A suspension of a particulate 
fraction of GFJ containing three one-hundredths the concentration of naringin (34 µmol/L) had 
no effect on fexofenadine exposure. The investigators concluded that naringin was a major 
causative ingredient inhibiting enteric OATP. However, the ∼50% difference in fexofenadine 
exposure between GFJ and naringin suggests other constituents contributed to the interaction. 
The furanocoumarins, bergamottin and 6′,7′-dihydroxybergamottin (DHB), and the 
polymethoxyflavones, tangeretin and nobiletin, have been reported to inhibit human enteric 
OATP activity in vitro.[12] Whether these observations translate to the clinic is not known. Based 
on the cumulative data, these two classes of GFJ constituents were evaluated as candidate OATP 
inhibitors by comparing the effect of a GFJ devoid of furanocoumarins and polymethoxyflavones 
(i.e., modified GFJ, mGFJ) with that of the original GFJ on fexofenadine disposition in both 
OATP-transfected cells and healthy volunteers. 
Methods 
Materials and Chemicals 
[3H]estrone 3-sulfate (E1S) ammonium salt (54.3 Ci/mmol) was purchased from Perkin Elmer 
(Waltham, MA). [3H]fexofenadine (6 Ci/mmol), originally a gift from GlaxoSmithKline 
(Research Triangle Park, NC) and custom synthesized by Amersham Life Sciences (Piscataway, 
NJ), was provided by Dr. Dhiren Thakker (Eshelman School of Pharmacy, Chapel Hill, NC). 
E1S potassium salt, verapamil (VER), bromosulfophthalein (BSP), bergamottin, DHB, naringin, 
hesperidin, tangeretin, and nobiletin were purchased from Sigma-Aldrich (St. Louis, MO). 
Fexofenadine was obtained from Tocris Bioscience (Minneapolis, MN). COS-1 and 
HEK293T/17 cells were obtained from American Type Culture Collection (Manassas, VA). Cell 
culture plates were purchased from Corning Life Sciences (Tewksbury, MA). Opti-MEM and 
Lipofectamine2000 were purchased from Invitrogen (Carlsbad, CA). X-tremeGENE 9 was 
purchased from Roche Applied Science (Indianapolis, IN). Human OATP1A2 (variant 1; 
accession number NM_134431.1) and OATP2B1 expression plasmids were obtained from 
Origene Technologies (Rockville, MD). Plasmids for mock-transfected cells, pEYFP-C1 and 
pcDNA3.1/Hygro(+), were purchased from Clontech (Mountain View, CA) and Invitrogen, 
respectively. MDCKII parental cells and stably transfected MDCKII–OATP2B1 cells were 
provided by Dr. Markus Grube (Ernst-Moritz-Arndt University, Greifswald, Germany). All other 
chemicals and reagents were purchased from Fisher Scientific (Pittsburgh, PA). 
Preparation of Whole and Modified Grapefruit Juice 
A commercial GFJ concentrate was obtained from a Florida processing facility and prepared as 
described previously.[5,13] The GFJ and mGFJ were re-pooled, re-pasteurized at 71.7°C for 
6 seconds, poured into sterilized bottles, and stored at −20°C until use. Representative 
compounds from the furanocoumarin, polymethoxyflavone, and flavanone classes were re-
measured by HPLC as described previously.[5,13] 
Preparation of Whole and Modified Grapefruit Juice Extracts 
Concentrated extracts of GFJ and mGFJ were prepared by adding 20 mL ethyl acetate to a 50-
mL conical polypropylene tube containing 25 mL juice. Contents were shaken vigorously for 
30 seconds and centrifuged (2,500g for 30 minutes at 25°C). The resulting organic layer was 
transferred to a 250-mL round-bottom glass flask. The extraction procedure was repeated twice, 
with each resultant organic layer combined in the flask. Organic layers were evaporated in 
vacuo. The residue was transferred to a 2-mL vial using methanol as a rinse and evaporated to 
dryness under air. The dried material was resuspended with 500 µL methanol, yielding a 200-
fold concentrated extract of the starting juice volume (100 mL). 
Transient Transfection of OATP1A2 and OATP2B1 Into COS-1 and HEK293T/17 Cells 
Human OATP1A2 and OATP2B1 expression plasmids were verified by DNA sequencing prior 
to use. COS-1 cells were maintained, seeded, and transfected transiently as described 
previously.[14] HEK293T/17 cells were cultured and maintained in Dulbecco's modified Eagle's 
medium supplemented with 10% fetal bovine serum at 37°C and 5% CO2. Cells were seeded on 
Day 0 onto 100-mm dishes and transfected on Day 1 using the X-tremeGENE9 transfection 
reagent per manufacturer instructions. Transfection efficiency was assessed on Day 2 with 
fluorescence microscopy by estimating the percentage of cells expressing EYFP (mock). On Day 
3, transfected cells were trypsinized, seeded onto 24-well plates, and incubated for 
approximately 48 hours before commencing the uptake assays. MDCKII parental cells and stably 
transfected MDCKII–OATP2B1 cells were cultured and maintained in a similar manner as 
HEK293T/17 cells. Cells were passaged once, seeded onto 24-well plates, and incubated for 
approximately 48 hours prior to initiating uptake studies. 
Uptake and Inhibition Assays 
On Day 4 or 5, cells were washed and preincubated for 30 minutes at 37°C in uptake buffer (pH 
6).[14] Buffer was replaced, and cells were incubated with a dosing solution (200 µL) consisting 
of radiolabeled (plus unlabeled) E1S (total: 5 µmol/L) or fexofenadine (total: 5 µmol/L) in the 
presence of vehicle (1% methanol), VER (250 µmol/L) and/or BSP (250 µmol/L), or diluted 
juice extract (1:200 and 2:200 to approximate single- and double-strength concentrations, 
respectively, of the clinical juice). After 3 (E1S) or 30 (fexofenadine) min, cells were washed 
thrice with ice-cold phosphate-buffered saline and lysed with either 0.1 N sodium hydroxide 
(COS-1 cells) or 1% Triton X-100 in phosphate-buffered saline (HEK293T/17 cells). Liquid 
scintillation cocktail (5 mL) was added to 200-µL aliquots of the cell lysates, and radioactivity 
was counted. Protein concentrations were determined with a bicinchoninic acid protein assay kit 
(Thermo Fisher Scientific, Waltham, MA). Uptake was linear over the selected times for each 
substrate (data not shown). 
Clinical Study Protocol 
The study protocol was reviewed and approved by the University of North Carolina Biomedical 
Institutional Review Board and Clinical and Translational Research Center (CTRC) Committee. 
Participants 
All subjects provided written informed consent prior to participation. Healthy volunteers (nine 
women, nine men) were enrolled. The median age (range) of the women and men was 30 (23–
54) and 37 (23–60) years, respectively. Participants were self-identified as Caucasian (seven 
women, five men), African-American (two women, two men), Asian (one man), or Hispanic 
(one man). Concomitant medications included oral/vaginal ring contraceptive therapy (two 
Caucasian women), hydrochlorothiazide (one Caucasian woman), low-dose aspirin (one African-
American man), multivitamin, calcium, folate, and ω-3 fatty acid supplements (three women, 
three men). Prior to enrollment, each volunteer underwent a medical history, physical 
examination, and laboratory tests (i.e., liver function tests, basic metabolic panel, complete blood 
count). All women underwent a serum pregnancy test. Subjects were instructed to abstain from 
all fruit juices for ≥7 days prior to and during the study and to abstain from alcohol- and 
caffeine-containing beverages the evening before each admission. Each subject was assigned 
randomly to one of six treatment sequences: ABC, CAB, BCA, CBA, BAC, or ACB (A = water, 
B = GFJ, C = mGFJ). 
Study Design 
Eligible volunteers were admitted to the CTRC the evening prior to each of three study phases, 
which were separated by ≥10 days. All women underwent a repeat serum pregnancy test on the 
evening of each admission. Following an overnight fast beginning at midnight and placement of 
an indwelling venous catheter in an antecubital vein, each subject ingested two 60 mg 
fexofenadine tablets (Prasco Laboratories, Mason, OH) with 240 mL water, GFJ, or mGFJ. 
Blood (7 mL) was collected into EDTA-containing tubes (Becton-Dickinson, Franklin Lakes, 
NJ) before and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours after fexofenadine administration. 
Subjects continued to fast until after the 4-hour blood collection, after which meals and snacks, 
devoid of fruit juices and caffeinated beverages, were provided. Vital signs were recorded at 
baseline and monitored periodically. Subjects were discharged after the 12-hour blood collection 
and returned for outpatient blood draws at 24, 36, 48, and 72 hours post-fexofenadine 
administration. Plasma was separated from blood cells by centrifugation within 1 hour of 
collection, transferred into cryovials, and stored at −80°C pending analysis for fexofenadine. 
Analysis of Plasma for Fexofenadine 
Plasma collections were processed by transferring 50 µL to a 96-well plate insert and 
precipitating proteins with 150 µL of methanol containing fexofenadine-d6 (1 nmol/L) as internal 
standard (Toronto Research Chemicals, Inc., Toronto, ON, Canada). The mixtures were vortex-
mixed for 5 minutes and centrifuged (3,000g for 10 minutes at 4°C). Calibration solutions 
(0.0012–7.2 µmol/L) and quality controls (0.005, 0.05, 0.1, 0.5, 1 µmol/L) were prepared 
similarly using fexofenadine and multiple-donor pooled plasma (Biological Specialty 
Corporation, Colmar, PA). Plasma was analyzed for fexofenadine by HPLC-tandem mass 
spectrometry using an API 4000 triple quadrupole with TurboIonSpray interface (Applied 
Biosystems/MDS Sciex, Concord, ON, Canada) as described.[15] Briefly, 5 µL were injected, and 
fexofenadine and fexofenadine-d6 were eluted from an Aquasil C18 column (2.1 mm × 50 mm, 
particle diameter = 5 µm; Thermo Fisher Scientific) using a mobile phase gradient (A: 0.1% 
formic acid in water; B: 0.1% formic acid in methanol) at a flow rate of 0.75 mL/min. The mass 
spectrometer was operated in positive-ion mode. Multiple reaction monitoring was used to detect 
fexofenadine (502 → 466 m/z) and fexofenadine-d6 (508 → 472 m/z). The lower limit of 
quantification was 0.0012 µmol/L; inter- and intra-day coefficients of variation were 12% and 
<15%, respectively, for the quality controls. 
Data Analysis 
OATP1A2- and OATP2B1-mediated uptake, in the absence or presence of inhibitor, was 
normalized for protein content. Net uptake was determined by subtracting the uptake in mock-
transfected cells from that in OATP1A2- and OATP2B1-expressing cells incubated under 
parallel conditions. 
Fexofenadine pharmacokinetics were evaluated by non-compartmental methods using 
WinNonlin (v 5.2, Pharsight Corp., Mountain View, CA). The terminal elimination rate constant 
(λz) was estimated by log-linear regression of at least the last three data points in the terminal 
phase of the plasma concentration–time profile. The terminal half-life (t½) was calculated as 
0.693/λz. The maximum concentration (Cmax), time to reach Cmax (tmax), and the last measured 
concentration (Clast) were determined visually from the concentration–time profile. AUC0–last was 
calculated using the trapezoidal rule with linear up/log down interpolation. AUC from zero to 
infinite time (AUC0–∞) was calculated as the sum of AUClast and Clast/λz. Apparent oral clearance 
(Cl/F) was calculated as Dose/AUC0–∞. Below limit of quantification concentrations were 
excluded from data analysis. 
Statistical Analysis 
Statistical analysis employed SigmaPlot (v 11, Systat Software, Inc., San Jose, CA). In vitro data 
are presented as means ± SDs of triplicate incubations. Two-way analysis of variance followed 
by Tukey's test was used to test for differences between vehicle and inhibitor treatments. 
Student's unpaired t-test was used to test for differences between mock- and OATP-transfected 
cells. A P-value < .05 was considered statistically significant. Pharmacokinetic outcomes (t½, 
Cmax, AUC0–∞, Cl/F) are reported as geometric means with coefficients of variation (CV%). 
Medians and ranges are reported for tmax. The Wilcoxon signed-rank test was used to compare 
tmax. Pharmacokinetic outcomes, expressed as the ratio of GFJ to water or GFJ to mGFJ, are 
reported as geometric means with 90% confidence intervals. Comparisons using one-tailed 
paired Student's t-tests (given the uni-directional nature of the interaction) with Bonferroni 
correction (i.e., 0.05/2) were used to detect differences between water and GFJ and between GFJ 
and mGFJ treatments. A P-value <.025 was considered statistically significant. Based on the 
method proposed by Lauzon and Caffo,[16] for the primary pharmacokinetic measure of interest, 
AUC, a minimum of 18 subjects who completed all treatment phases was deemed adequate for 
this study, assuming a within-subject CV of 23% for fexofenadine determined from a previous 
study.[10] The randomization scheme was generated using SAS (v 9.2, SAS Institute, Inc., Cary, 
NC). 
Results 
Representative Furanocoumarin, Polymethoxyflavone, and Flavanone Concentrations in 
Grapefruit Juice and Modified Grapefruit Juice 
Due to the >5-year lapse since last use,[5,13] GFJ and mGFJ were re-analyzed for representative 
compounds from each of three phytochemical classes shown to inhibit intestinal OATP activity 
in vitro (Table 1). Relative to GFJ, the representative furanocoumarins DHB and bergamottin in 
mGFJ were reduced by >99% and 95%, respectively. The representative polymethoxyflavones 
nobiletin and tangeretin were reduced by 95% and 73%, respectively. The representative 
flavanones naringin, narirutin, and hesperidin were reduced by ∼30%, 32%, and 44%, 
respectively. Mean (±SD) aggregate representative furanocoumarins, polymethoxyflavones, and 
flavanones measured in GFJ (48 ± 1, 0.48 ± 0.03, and 1,064 ± 10 µmol/L, respectively) and in 
mGFJ (0.6 ± 0.1, 0.05 ± 0.02, and 727 ± 14 µmol/L, respectively) were consistent with those 
measured initially (GFJ: 59 ± 2, 0.71 ± 0.03, and 1,012 ± 24 µmol/L; mGFJ: 0.3 ± 0.01, 
0.03 ± 0.01, and 787 ± 69 µmol/L).[5,13] The net loss of ≤3% indicated negligible degradation over 
the >5-year storage period. 
Table 1. Concentrations of Representative Furanocoumarins, Polymethoxyflavones, and 
Flavanones in Grapefruit Juice (GFJ) and Modified GFJ (mGFJ) 
Constituent Mean Concentration (µmol/L) (SD) 
GFJ mGFJ 
Furanocoumarins 
DHB 38.8 (0.3) 0.13 (0.01) 
Bergamottin 9.07 (0.04) 0.50 (0.08) 
Polymethoxyflavones 
Nobiletin 0.37 (0.02) 0.02 (0.01) 
Tangeretin 0.11 (0.01) 0.03 (0.01) 
Flavanones 
Naringin 770 (5) 531 (8) 
Narirutin 271 (4) 183 (5) 
Hesperidin 24.6 (1.2) 14.7 (0.6) 
DHB, 6′,7′-dihydroxybergamottin. 
Effects of Grapefruit Juice and Modified Grapefruit Juice Extracts on Estrone 3-Sulfate 
and Fexofenadine Uptake in OATP-Transfected Cells 
Ethyl acetate extracts of GFJ and mGFJ were evaluated as inhibitors of OATP1A2- and 
OATP2B1-mediated uptake in COS-1 and HEK293T/17 cells using the probe substrate estrone 
3-sulfate (E1S) to assess functional activity of the juices prior to clinical study conduct. Both 
juice extracts inhibited E1S uptake in COS-1 cells by at least 50% relative to vehicle (Figure 1A 
and B). Single-strength GFJ and mGFJ extracts inhibited OATP1A2-mediated uptake by 70% 
and 80%, respectively; double-strength extracts inhibited uptake by 84% and 50%, respectively 
(Figure 1A). Single-strength GFJ and mGFJ extracts inhibited OATP2B1-mediated uptake by 
78% and 61%, respectively; double-strength extracts inhibited uptake by 52 and 74%, 
respectively (Figure 1B). Both juice extracts inhibited E1S uptake in HEK293T/17 cells by at 
least 45% relative to vehicle (Figure 1C and D). Single-strength GFJ and mGFJ extracts 
inhibited OATP1A2-mediated uptake by 90% and 62%, respectively; double-strength extracts 
inhibited uptake by 80% and 74%, respectively (Figure 1C). Single-strength GFJ and mGFJ 
extracts inhibited OATP2B1-mediated uptake by 74% and 59%, respectively; double-strength 
extracts inhibited uptake by 60% and 45%, respectively (Figure 1D). BSP, a non-specific OATP 
inhibitor, inhibited uptake by >80% in all cell systems. 
 
Figure 1. Inhibitory effects of grapefruit juice extracts (GFJ, mGFJ) on estrone 3-sulfate (E1S) uptake in 
COS-1 (A and B) and HEK293T/17 (C and D) cells overexpressing human OATP1A2 (A and C) or 
OATP2B1 (B and D). Cells were transiently transfected with human OATP1A2, OATP2B1, or mock 
(EYFP) plasmids. Cells were incubated for 3 minutes in pH 6.0 buffer at 37°C with 0.05 µmol/L [3H]E1S 
in the presence of vehicle (1% methanol) or GFJ and mGFJ extracts at single-strength (1×) or double-
strength (2×). Bromosulfophthalein (BSP) (250 µmol/L) was used as a positive control inhibitor. E1S 
mean net uptake by OATP1A2 in the presence of vehicle was 17.5 ± 3.2 and 17.3 ± 1.1 pmol/mg 
protein/3 minutes, for COS-1 and HEK293T/17 cells, respectively. E1S mean net uptake by OATP2B1 in 
the presence of vehicle was 42.7 ± 3.0 and 17.7 ± 3.5 pmol/mg protein/3 minutes for COS-1 and 
HEK293T/17 cells, respectively. Bars and error bars denote means and SDs, respectively, of triplicate 
incubations. *P < .05 versus vehicle (two-way ANOVA followed by Tukey's test), #P < .05 versus GFJ 1× 
(two-way ANOVA followed by Tukey's test), †P < .05 versus GFJ 2× (two-way ANOVA followed by 
Tukey's test), ‡P < .05 versus mGFJ 1× (two-way ANOVA followed by Tukey's test). 
COS-1 cells transiently overexpressing OATP1A2 were employed initially to gain mechanistic 
insight into inhibition of fexofenadine uptake by GFJ and mGFJ. Due to high uptake activity in 
mock (EYFP)-transfected cells with the juice extracts and BSP (Figure 2A), OATP1A2 was 
expressed transiently in HEK293T/17 cells, in which uptake in mock-transfected cells was more 
consistent (Figure 2B). Relative to vehicle-treated OATP1A2-transfected cells, both single- and 
double-strength GFJ extract inhibited fexofenadine uptake by ∼27%. Both single- and double-
strength mGFJ extract inhibited uptake by ∼40%. Because BSP did not inhibit fexofenadine 
uptake in HEK293T/17 cells, VER was used as an alternate OATP1A2 inhibitor, inhibiting by 
∼50%. 
 
Figure 2. Inhibition of fexofenadine uptake by grapefruit juice extracts (GFJ, mGFJ) in OATP1A2-
transfected cells. COS-1 (A) and HEK293T/17 (B) cells were transiently transfected with human 
OATP1A2 (black bars) or mock (EYFP) plasmids (gray bars). Cells were incubated for 30 minutes in pH 
6.0 buffer at 37°C with 0.5 µmol/L [3H]fexofenadine in the presence of vehicle (1% methanol) or GFJ and 
mGFJ extracts at single-strength (1×) or double-strength (2×). Bromosulfophthalein (BSP) and verapamil 
(VER) (250 µmol/L) were used as positive control inhibitors. Fexofenadine mean net uptake by 
OATP1A2 in the absence of juice extracts was 12.8 ± 1.1 and 39.4 ± 4.8 pmol/mg protein/30 minutes, for 
COS-1 and HEK293T/17 cells, respectively. Bars and error bars denote means and SDs, respectively, of 
triplicate incubations. *P < .05 versus mock-transfected cells (Student's unpaired t-test). #P < .05 versus 
vehicle-treated OATP1A2-transfected cells (two-way ANOVA followed by Tukey's test). 
OATP2B1-mediated uptake of fexofenadine was evaluated in transiently transfected COS-1 and 
stably transfected MDCKII cells (Figure 3). Due to the possibility of cell line-dependent 
expression/uptake, OATP2B1 was expressed in HEK293T/17 cells. Fexofenadine uptake was not 
observed with any cell line. 
 
Figure 3. Fexofenadine uptake in OATP2B1-transfected cells. Transiently transfected COS-1 cells and 
HEK293T/17 cells and stably transfected MDCKII cells were incubated for 30 minutes in pH 6.0 buffer at 
37°C with 0.5 µmol/L [3H]fexofenadine. Estrone 3-sulfate (E1S) was used as a positive control; fold-
difference between control and transfected cells was 4, 5, and 20 for COS-1, MDCKII, and HEK293T/17 
cells, respectively. Black bars denote OATP2B1-mediated uptake. Gray bars denote mock-transfected 
(COS-1, HEK293T/17) or parental cell uptake (MDCKII). Bars and error bars denote means and SDs, 
respectively, of triplicate incubations. 
Effects of Grapefruit Juice and Modified Grapefruit Juice on Fexofenadine 
Pharmacokinetics in Healthy Volunteers 
The effects of GFJ and mGFJ on fexofenadine pharmacokinetics were compared in 18 healthy 
participants. None of the participants withdrew from the study. Each treatment was well tolerated 
by all participants. No side effects were reported. 
The geometric mean concentration–time profiles of fexofenadine in the presence of GFJ and 
mGFJ were nearly superimposable (Figure 4). The percentage of fexofenadine AUC extrapolated 
to infinite time (AUC0–∞) was <10% in all subjects and in all phases. Relative to water, GFJ and 
mGFJ decreased geometric mean AUC0–∞ by ∼25% (Table 2). The geometric mean AUC0–∞s 
were similar between GFJ and mGFJ (Table 2). Both juices increased geometric mean Cl/F by 
∼33% (Table 2). Relative to water, both juices decreased geometric mean Cmax by ∼23% 
(Table 2). The geometric mean terminal t½ and median tmax did not differ between treatments 
(Table 2). 
 
Figure 4. Geometric mean plasma fexofenadine concentration–time profile following co-administration 
with 240 mL of water, grapefruit juice (GFJ), or modified GFJ (mGFJ) for 18 healthy volunteers. 
Symbols and error bars denote geometric means and upper limits of the 90% confidence interval, 
respectively. Inset depicts the 0–72 hours profile. The 2-hour time point of the water phase represents the 
geometric mean of 17 subjects. Open circles, closed squares, and closed triangles denote water, GFJ, and 
mGFJ, respectively. 
Table 2. Pharmacokinetics of Fexofenadine (120 mg) in 18 Healthy Volunteers After 
Administration With 240 mL of Water, Grapefruit Juice (GFJ), or Modified GFJ (mGFJ) 
Outcome Geometric Mean (CV%) Geometric Mean Ratio (90% 
CI) 
Water GFJ mGFJ GFJ/Water GFJ/mGFJ 
 AUC0–∞ (µmol/L h) 4.22 
(40.0) 
3.22a (33.5) 3.15 
(28.6) 
0.76 (0.3–1.4) 0.98 (0.4–1.5) 
Cl/F (L/h) 52.8 
(40.0) 
69.3b (33.5) 70.9 
(29.6) 
1.31 (0.70–
1.92) 
1.02 (0.45–
1.60) 
Cmax (µmol/L) 0.57 
(52.2) 
0.45c (43.7) 0.44 
(32.4) 
0.78 (0.17–
1.39) 
0.97 (0.35–
1.60) 
t½ (h) 11.9 
(36.5) 
10.3d (37.6) 10.3 
(29.7) 
0.86 (0.28–
1.45) 
1.01 (0.43–
1.58) 
tmax (h) [median 
(range)] 
3 (1–6) 3.5e (1.5–5) 4 (2–6)     
AUC0–∞, area the curve from time zero to infinity; Cl/F, apparent oral clearance; Cmax, maximum 
concentration; t½, terminal half-life; tmax, time to Cmax. 
Statistical comparisons for all outcomes except tmax were made between water and GFJ and 
between GFJ and mGFJ using a one-tailed paired Student's t-test with Bonferroni correction 
(p < 0.025). 
a P = 0.008. 
b P = 0.023. 
c P = 0.011. 
d P = 0.11. 
e P = 0.135 (Wilcoxon signed-rank test). 
 
Discussion 
Since discovery of the fruit juice–OATP interaction, candidate inhibitors of OATP isoforms such 
as OATP1A2 and OATP2B1 have been proposed and evaluated for effects on intestinal and 
hepatic drug uptake.[17-20] The GFJ and mGFJ tested in the current work were compared 
previously in two clinical studies involving the CYP3A substrate felodipine and the dual 
CYP3A/P-gp substrate cyclosporine. The felodipine study established furanocoumarins, in 
aggregate, as major inhibitors of enteric CYP3A.[5] The cyclosporine study further substantiated 
furanocoumarins as major inhibitors of enteric CYP3A, and likely P-gp; in addition, 
polymethoxyflavones were ruled out as inhibitors of enteric P-gp.[13] Based on these 
observations, this unique GFJ-mGFJ combination enabled both in vitro and clinical evaluation of 
the collective impact of furanocoumarins and polymethoxyflavones on the absorption of a 
growing class of drugs whose enteric uptake depends on OATPs. Because no “clean” OATP 
substrates suitable for human use have been identified, coupled with prior knowledge of the 
GFJ–fexofenadine interaction,[6-10] fexofenadine was selected as a third prototypic probe 
substrate to test with this GFJ and mGFJ. 
Before clinical testing, both the original GFJ and mGFJ were evaluated for OATP inhibitory 
activity using OATP1A2- and OATP2B1-overexpressing cell systems and the probe substrate 
E1S. Compared to vehicle, both juice extracts inhibited both OATP isoforms by >50% in COS-1 
and HEK293T/17 cells. Inhibition of E1S uptake by both extracts also was observed in stably 
transfected MDCKII–OATP2B1 cells (data not shown) and was consistent with previous 
observations with stably transfected HEK293 cells and dilutions of whole GFJ.[12] The similar 
extents of OATP inhibition by the two extracts in HEK293T/17 cells predicted that systemic 
fexofenadine exposure in the clinical study would be comparable between juice treatments. 
As anticipated, relative to water, GFJ decreased the geometric mean systemic exposure (AUC, 
Cmax) to fexofenadine. This observation, coupled with the lack of an effect on geometric mean 
terminal half-life, was consistent with inhibition of uptake in the intestine by GFJ. The decrease 
in AUC (∼25%) was lower than that reported in previous GFJ–fexofenadine studies (31–67%),[6-
10] which could be attributed to the highly variable concentrations of bioactive ingredients among 
commercial brands and batches of GFJ.[21, 22] The modest decrease in AUC reflects considerable 
interindividual variability in magnitude of effect, which ranged from −68 to +57% among the 18 
subjects. This variability could be attributed in part to polymorphisms in the genes that encode 
for OATP (SLCO), as well as P-gp (MDR1); however, genotyping for relevant polymorphisms 
was beyond the scope of this study. 
As predicted by the enteric OATP-transfected cells using E1S as the probe substrate, mGFJ 
decreased geometric mean systemic fexofenadine exposure to a similar extent as GFJ. The nearly 
identical effects by both juices on fexofenadine pharmacokinetics indicated furanocoumarins and 
polymethoxyflavones are not major mediators of the GFJ–fexofenadine interaction. Elimination 
of furanocoumarins as major in vivo inhibitors of enteric OATPs is consistent with the single 
clinical study involving 12 healthy volunteers administered fexofenadine (120 mg) and an 
aqueous suspension (300 mL) of a particulate fraction of GFJ, which contained mostly 
furanocoumarins (measurements not provided) and a relatively trivial concentration (34 µmol/L) 
of the flavanone naringin.[10] Fexofenadine AUC in the presence of the particulate fraction was 
similar to that in the presence of water. Naringin also was tested in the same clinical study[10] at 
the same concentration as that in whole GFJ (∼1,200 µmol/L); the single constituent explained 
only half of the reduction in fexofenadine exposure caused by GFJ, indicating other constituents, 
possibly other flavanones (e.g., narirutin, hesperidin), contribute to the interaction. 
As aforementioned, fexofenadine is not a clean OATP substrate. Numerous investigators have 
shown that fexofenadine also is a P-gp substrate.[23-27] The diluted extracts of the clinically 
administered juices were tested as inhibitors of fexofenadine uptake in various OATP1A2- or 
OATP2B-transfected kidney-derived cell lines. Initial optimization studies with COS-1 cells 
demonstrated that fexofenadine was a weak substrate for OATP1A2. Low fexofenadine uptake 
by OATP1A2, coupled with high background activity, rendered difficulty in ascertaining the 
effects of the juice extracts. However, unlike COS-1 cells, the juice extracts did not significantly 
alter fexofenadine uptake in mock-transfected HEK293T/17 cells. Due to higher fexofenadine 
uptake activity in OATP1A2-transfected HEK293T/17 cells, comparable inhibition by both juice 
extracts was demonstrated. In addition to P-gp and OATP, apical and basolateral efflux mediated 
by multidrug resistant protein (MRP) 2 and MRP3, respectively, have been shown to contribute 
to fexofenadine transport in vitro.[28] Studies with transiently transfected COS-1 and 
HEK293T/17 cells, as well as stably transfected MDCKII cells, demonstrated that fexofenadine 
is not a substrate for OATP2B1. Conflicting in vitro data have been reported regarding 
OATP2B1-mediated transport of fexofenadine. Fexofenadine uptake in transiently transfected 
HeLa and stably transfected HEK293 cells either was not evident or was weak.[9, 29, 30] However, 
an independently generated MDCKII–OATP2B1 cell line showed an ∼3-fold difference in 
fexofenadine uptake compared to mock-transfected cells.[28] Fexofenadine has been shown to be 
a substrate of OATP2B1 in a Xenopus laevis oocyte system.[31] The discrepancy between in vitro 
experiments with fexofenadine may be attributed to multiple binding sites on OATP2B1 with 
different affinities, but to date, substrate-dependent binding has been demonstrated only with 
transfected oocytes.[32] 
In summary, current in vitro and clinical observations collectively indicate that furanocoumarins 
and polymethoxyflavones are not major mediators of the GFJ–fexofenadine interaction. 
Flavanones are likely candidate inhibitors of enteric OATPs in vivo. In vitro and clinical studies 
accounting for natural product ingredient composition are essential for appropriate evaluation, 
translation, and optimal pharmacotherapeutic management of GFJ- and other natural product–
drug interactions. A bioactivity-guided fractionation approach similar to that used to identify 
intestinal CYP3A inhibitors in cranberry[33] and hepatic OATP inhibitors in Rollinia 
emarginata[34] can be used to identify specific causative ingredients. Identification of such OATP 
inhibitors would enable evaluation and prediction of the interaction liability of GFJ and other 
foods containing the same compounds with other existing and potential OATP substrates, 
including some fluoroquinolones, beta-blockers, and statins.[35] Finally, confirmation of 
causative mediators may impact food manufacturing practices, leading to advances designed to 
minimize interference with drugs, including removal of compounds via chemical processing[5] or 
plant gene engineering.[36] 
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